Vokanamet

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vokanamet

Quick Facts

Property Description
Active Ingredients Canagliflozin and Metformin Hydrochloride
Form Film-coated tablet (Oral)
Pharmacological Class SGLT2 inhibitor and Biguanide (Antidiabetic)
Common Use Improving glycemic control in Type 2 diabetes mellitus
Origin Synthetic

What Type of Medicine is Vokanamet?

Vokanamet is a prescription-only antidiabetic medicine that is primarily recognized as a fixed-dose combination product intended for oral administration in adults with Type 2 diabetes mellitus. This synthetic drug, presented as a film-coated tablet, is utilized as a dual-action antidiabetic therapy that is clinically recognized for addressing the core deficiencies of high blood sugar. The fixed-dose design is a key feature, offering simplified medication management for patients needing both active components simultaneously.

Composition and Pharmacological Class of Vokanamet

Vokanamet contains two distinct active ingredients: Canagliflozin and Metformin Hydrochloride. These components belong to separate, yet complementary, pharmacological classes. Canagliflozin is classified as a Sodium-Glucose Co-transporter 2 (SGLT2) inhibitor, while Metformin Hydrochloride is a long-established drug of the biguanide class. The inclusion of the biguanide component marks the formulation as distinct from single-entity SGLT2 inhibitor drugs.

What is the General Purpose of Vokanamet?

The general purpose of Vokanamet is to contribute to a sustained improvement in glycemic control when used as an adjunct to diet and exercise. A typical neutral use scenario involves adults whose blood sugar remains inadequately controlled after taking Metformin alone. The drug's design allows it to leverage the insulin-independent mechanism of action of the SGLT2 inhibitor alongside the established benefits of the biguanide component, directly addressing the chronic challenges of elevated blood sugar associated with Type 2 diabetes.

What side effects are possible with Vokanamet?

Possible Side Effects and Safety Information

The safety profile of Vokanamet (Canagliflozin/Metformin) is structured around adverse reactions linked to its two active components, based on authoritative regulatory documentation. Reactions are classified by frequency and body system involvement.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Very Common (≥ 1/10) Hypoglycaemia (when used with insulin/sulfonylurea), Female genital mycotic infections.
Common (≥ 1/100 to < 1/10) Urinary tract infection, Polyuria (increased urination), Constipation, Lower limb amputations, Nausea, Thirst.
Uncommon (≥ 1/1,000 to < 1/100) Hypotension (low blood pressure), Dizziness, Bone fracture.
Rare to Very Rare Anaphylactic reaction, Lactic acidosis.

Serious Adverse Reactions and Safety Constraints

Regulatory agencies highlight several serious risks and necessary limitations. The Metformin component carries a risk of Lactic Acidosis, a rare but serious metabolic event, which contributes to the drug being contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2) or hepatic impairment.

The Canagliflozin component is associated with warnings for Diabetic Ketoacidosis (DKA), Fournier's Gangrene (a rare perineal infection), and an increased risk of Lower Limb Amputation.

Monitoring of renal function (eGFR/CrCl) is required before and regularly during treatment. The drug must be temporarily discontinued before certain radiological procedures involving iodinated contrast agents and elective surgery.

Population-specific notes include increased caution for volume depletion and hypotension in elderly patients.

Overdose and Emergency Response

The official regulatory profile for Vokanamet overdose focuses on the distinct risks posed by its two active components, defining a potentially severe metabolic emergency. The primary concern is the development of Lactic Acidosis due to the Metformin component, a documented life-threatening outcome that may present initially with nonspecific symptoms.

Documented clinical manifestations of this condition include acidotic dyspnoea (trouble breathing), unusual somnolence (drowsiness), myalgias (muscle pain), vomiting, and abdominal pain. Overdose with the Canagliflozin component is documented to cause signs of volume depletion, such as excessive thirst and increased urination.

In severe cases, the outcomes of Lactic Acidosis can escalate to coma, seizures, and cardiovascular collapse. These life-threatening symptoms, or any suspicion of Lactic Acidosis, mandate that the patient must immediately stop taking Vokanamet and seek immediate medical attention.

For overdose management, regulatory documents state that no specific antidotes are available. Treatment is restricted to symptomatic and supportive measures, with Hemodialysis explicitly recommended to clear the Metformin component and correct severe acidosis. The risk of Lactic Acidosis is noted to be increased in the elderly and in patients with pre-existing renal impairment.

Therapeutic Uses of Vokanamet

What Vokanamet Treats: Main Uses and Benefits

The primary therapeutic area for Vokanamet is supporting the management of Type 2 Diabetes Mellitus and addressing the symptomatic burden of persistently high blood sugar (hyperglycemia). It is commonly used as an add-on therapy for adults whose blood sugar levels may not be adequately controlled using metformin alone or with diet and exercise. This is commonly used to support management of the factors that lead to persistently high metabolic markers, such as glycosylated hemoglobin (HbA1c) levels.

The medication may be part of the management strategy for systemic risk factors in adults with T2DM, particularly those with established atherosclerotic cardiovascular disease and diabetic kidney disease (nephropathy). It is considered relevant in contexts involving high cardiovascular risk, and may help support the management of conditions that create noticeable physiological strain linked to cardiovascular risk. The medication is used to control blood glucose in adults with Type 2 diabetes whose disease is not satisfactorily managed by existing treatment.

The therapeutic approach is relevant for easing systemic imbalance and assists with maintaining functional stability related to kidney health. Furthermore, the fixed-dose format assists in simplifying the daily medication regimen, which may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Systemic Imbalance
Common Uses Managing Type 2 Diabetes Mellitus when blood sugar is inadequately controlled on metformin, and supporting systemic risk management in patients with cardiovascular or kidney disease.

Eligibility and Restrictions for Use

Vokanamet is officially indicated for use in adults with Type 2 Diabetes Mellitus. Eligibility is strictly defined by regulatory guidelines concerning age, organ function, and specific disease states. While European regulators classify safety as not established in children under 18 years of age, the U.S. label permits use in pediatric patients aged 10 and older.

Use is absolutely prohibited (contraindicated) in several populations. These include patients with Type 1 Diabetes Mellitus or any form of acute metabolic acidosis, such as lactic acidosis or diabetic ketoacidosis. A history of serious hypersensitivity reaction to the active ingredients (Canagliflozin or Metformin) also prohibits use.


Organ Function and Condition Restrictions

Eligibility is highly dependent on renal and hepatic function. The medicine is contraindicated in patients with severe renal impairment (eGFR below 30 mL/ min/ 1.73 m^2), end stage renal disease, or any degree of hepatic impairment. Restrictions also apply during acute conditions that may impair kidney function, such as severe infection, necessitating temporary discontinuation. The medicine is not recommended during the second and third trimesters of pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official government drug labeling documents specific interaction patterns that can alter the activity or concentration of Canagliflozin or Metformin Hydrochloride.


Interacting Substances and Effects

Classification Interacting Agents (Examples) Official Regulatory Effect Exposure Alteration
UGT Inducers Rifampin, Phenytoin, St. John's Wort UGT enzyme induction affects Canagliflozin Reduces Canagliflozin exposure
P-gp Substrates Digoxin, Digitoxin Canagliflozin inhibition of P-gp Increases Digoxin concentration
Cationic Drugs Cimetidine, Dolutegravir Competition for renal transporters Increases Metformin accumulation
Antidiabetics Insulin, Sulfonylureas Additive pharmacodynamic effect Increased risk of hypoglycemia

Interaction Restrictions and Constraints

Co-administration with iodinated contrast media requires the medicine to be temporarily discontinued at the time of or prior to the radiological procedure. The drug is only to be restarted after the procedure when renal function has been re-evaluated and found to be normal. Additionally, excessive alcohol intake is restricted as it potentiates the Metformin-related risk of lactic acidosis. The medicine must also be stopped during and for some time after major surgery. Population-specific notes specify that the drug is contraindicated in patients with severe renal impairment (eGFR below 45 mL/min/1.73 m^2) due to the risk of Metformin accumulation.

Mechanism of Action

How Vokanamet Works

Vokanamet operates through two distinct and complementary mechanistic domains to modify the physiological processes that regulate plasma glucose.


Renal Excretion: The Insulin-Independent Pathway

The Canagliflozin component acts as a competitive inhibitor of the Sodium-Glucose Co-transporter 2 ( SGLT2) protein, which is primarily located in the kidneys' proximal tubules. By blocking this transporter, the drug prevents the reabsorption of most of the filtered glucose back into the systemic circulation. This molecular blockade leads directly to an increase in Urinary Glucose Excretion ( UGE), initiating a physiological cascade that results in a net removal of glucose from the systemic circulation.


Metabolic Control: Suppressing Production and Enhancing Utilization

The Metformin component primarily targets the liver, where it modulates the cellular energy balance by affecting Mitochondrial Respiratory Chain Complex I. This cascade leads to the activation of AMP-activated protein kinase ( AMPK), which in turn suppresses the process of Hepatic Glucose Production ( HGP). Additionally, this mechanism supports the enhanced utilization of circulating glucose by peripheral tissues. This dual action modifies the production and utilization of glucose within the body.


Complementary Dual-Pathway Modulation

The primary mechanistic relevance of this combination lies in its mechanistic independence. Canagliflozin provides a direct means of glucose removal, while Metformin addresses metabolic function by suppressing production and improving utilization. The combined mechanisms provide a multifaceted and coordinated modification of the physiological processes governing glucose homeostasis.

Dosage and Administration Information

Vokanamet is administered exclusively by the oral route as a film-coated tablet and must be swallowed whole with water. The regimen requires twice daily (BID) dosing, and the tablets are taken with meals to reduce the gastrointestinal effects associated with the metformin component.

The dosing schedule is highly individualized, reflecting the need to align the combination product with a patient's existing therapeutic needs. The total daily dose of the Canagliflozin component typically starts at 100 mg, administered as 50 mg twice daily. Dose escalation to the maximum total daily dose of 300 mg (150 mg twice daily) for the Canagliflozin component is permissible in patients who tolerate the lower dose and require tighter glycemic management. The Metformin component's maximum total daily dose is 2,000 mg.

Specific limitations apply for certain populations. For patients with moderately reduced kidney function (estimated glomerular filtration rate between 45 and 60 mL/min/1.73 m^2), the maximum total daily dose of the Canagliflozin component is limited to 100 mg. Furthermore, if a dose is missed, the standard practice is to take it as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose is skipped entirely. The medicine is intended for use as part of a long-term management plan for Type 2 diabetes.

Recent Clinical Evidence

Research Evidence / Overview of Studies

The fixed-dose combination of Vokanamet contains canagliflozin and metformin and has been evaluated in a comprehensive global Phase 3 clinical development program for the canagliflozin component, often used alongside metformin as background therapy.

Glycemic Control Studies

Clinical trials have primarily focused on the effectiveness of adding canagliflozin to a regimen already including metformin. Studies consistently showed that the combination was associated with a greater reduction in glycosylated hemoglobin (HbA1c)—a key marker of long-term blood sugar control—compared to placebo (dummy treatment) added to metformin alone. Reductions in HbA1c levels were generally sustained over observation periods of up to 104 weeks.

Additional findings from the Phase 3 program also reported:

  • Body Weight and Blood Pressure: The combination was associated with modest reductions in both body weight and systolic blood pressure when compared to comparator treatments or placebo added to background metformin.

Cardiovascular and Safety Outcomes

Specific large-scale, long-term trials have examined the cardiovascular and safety profile of canagliflozin in patients with type 2 diabetes and high cardiovascular risk:

Trial Focus Key Observation
Cardiovascular Risk Studies explored potential effects on major cardiovascular events.
Amputation Risk (CANVAS) Long-term data suggested an increased incidence of lower limb amputations (primarily toes/mid-foot) compared to placebo in high-risk patients. This risk was observed to be independent of pre-existing risk factors, though the absolute risk was higher in patients with existing peripheral vascular disease or neuropathy.

Adverse events related to the mechanism of canagliflozin (a SGLT2 inhibitor) were observed in trials, including genital mycotic infections and events related to osmotic diuresis (such as volume depletion). These were typically mild to moderate in intensity and led to few discontinuations.

Key Studies & References

  1. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (The CANVAS Program)
  2. Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis (Used for HbA1c, FPG, and combination therapy efficacy)
  3. Network meta-analysis of sodium–glucose co-transporter 2 inhibitors and comparators in monotherapy (Includes data on blood pressure and weight reduction)

Frequently Asked Questions (FAQ)

Common questions about Vokanamet (FAQ)


Q: How quickly does Vokanamet start working to lower blood sugar?

A: The canagliflozin component (SGLT2 inhibitor) begins increasing glucose removal via urine shortly after the first dose. In clinical studies, the full effect on long-term blood sugar control ( HbA1c) has generally been observed after several weeks or months of consistent use.


Q: What are the most common side effects people report when starting Vokanamet?

A: Official product information states that the most common side effects (Very Common, more than 1 in 10 patients) include female genital fungal infections and low blood sugar (hypoglycemia) when the medicine is combined with insulin or a sulfonylurea. Additionally, gastrointestinal side effects like nausea and diarrhea are very common due to the metformin component.


Q: Is it normal to urinate more often when taking Vokanamet?

A: Yes, increased urination, or polyuria, is a common side effect of this medication. This is related to the way the canagliflozin component works in the kidneys, which involves removing excess sugar by increasing the amount of water in the urine.


Q: Does Vokanamet make you feel tired or fatigued?

A: General fatigue is not listed as a common or very common side effect in the product labeling. However, unusual tiredness or weakness ( asthenia) is a symptom associated with the rare but serious risk of lactic acidosis, a risk connected to the metformin component.


Q: Do I need to change my diet while taking Vokanamet?

A: Official prescribing information indicates that this medicine is intended to be used as an adjunct to diet and exercise for improving blood sugar control. Regulatory information specifies that excessive alcohol intake should be restricted, as this can increase the risk of a serious side effect called lactic acidosis.


Q: Why do some people experience stomach upset with the metformin part of Vokanamet?

A: Gastrointestinal side effects, such as nausea and diarrhea, are commonly associated with the metformin component. To help mitigate the occurrence of these gastrointestinal effects, official administration instructions specify that the tablet should be taken with meals.


Q: Can older adults safely take Vokanamet?

A: Older adults may be at an increased risk for side effects related to volume depletion (dehydration) and low blood pressure (hypotension). For this reason, product labeling notes that assessment of renal function is recommended more frequently in older patients.


Q: Is it safe to drink alcohol in moderation while taking Vokanamet?

A: Regulatory documents advise that excessive alcohol intake must be restricted because it can increase the risk of lactic acidosis, a rare but very serious side effect of the metformin component.


Q: Does Vokanamet interact with blood pressure medications?

A: Yes, using Vokanamet with certain blood pressure medications, particularly diuretics (water pills), may increase the risk of adverse reactions related to volume depletion and hypotension (low blood pressure). The importance of disclosing all medications to a healthcare provider is noted in prescribing information.


Q: Can Vokanamet be taken at the same time as other diabetes medicines?

A: Vokanamet can be used with other diabetes medicines. However, when the medicine is used in combination with an insulin secretagogue (like a sulfonylurea) or insulin, the risk of low blood sugar (hypoglycemia) is increased, and dose adjustments of the concomitant medicine may be necessary.


Q: What are some signs that Vokanamet is working?

A: The primary way the medicine is shown to be working is by a reduction in long-term blood sugar levels, measured by HbA1c. Studies also indicate that patients may experience modest reductions in body weight and systolic blood pressure.


Q: Is Vokanamet a type of insulin?

A: No, Vokanamet is not insulin. It is a dual-action oral antidiabetic medicine combining an SGLT2 inhibitor (canagliflozin) and a Biguanide (metformin). It works through different mechanisms than insulin to help control blood sugar.


Q: Why did my doctor prescribe Vokanamet instead of just metformin?

A: Official labeling states the medicine is for adults whose blood sugar is not adequately controlled by the maximal tolerated dose of metformin alone. It provides two complementary ways to manage blood sugar when one drug is not enough.


Q: Does Vokanamet help with weight loss?

A: Clinical trials associated the use of this medicine with modest reductions in body weight when compared to patients receiving placebo added to their background therapy.


Q: Can Vokanamet affect kidney function over time?

A: Regulatory information notes a risk of acute kidney injury requiring monitoring. The canagliflozin component has also been studied for its potential to reduce the risk of worsening kidney problems in patients with established diabetic kidney disease.


Q: Is Vokanamet safe to take if I have heart problems?

A: The canagliflozin component is indicated in some patients to reduce the risk of major adverse cardiovascular events like heart attack and stroke. The use of the medicine in patients with heart problems is a clinical decision that requires evaluation of individual cardiovascular risk.


Q: What are the signs of a serious, but rare, side effect like ketoacidosis with Vokanamet?

A: Signs of ketoacidosis (a serious buildup of acids in the blood) include nausea, vomiting, abdominal pain, generalized malaise (feeling unwell), and shortness of breath. This can occur even if blood sugar levels are not extremely high.


Q: What happens if I stop taking Vokanamet suddenly?

A: The effects of the medicine will gradually wear off. The unique action of the canagliflozin component, which increases glucose removal, is shown to persist for about three days after the last dose.


Q: Does Vokanamet interact with herbal supplements?

A: Official information notes that some herbal products, such as St. John’s Wort, can reduce the amount of the canagliflozin component in the blood, potentially making the medicine less effective.


Q: Do I need any special monitoring tests while on Vokanamet?

A: Yes, due to a risk of Vitamin B12 deficiency associated with the metformin component, official guidance recommends the monitoring of Vitamin B12 levels and blood counts annually.


Q: Can Vokanamet affect vitamin B12 levels?

A: Yes, the metformin component has been shown to potentially lower Vitamin B12 levels. Because of this, monitoring of B12 levels is recommended during the course of treatment.


Q: What is the connection between Vokanamet and foot health?

A: Studies indicated an increased risk of lower limb amputations (primarily of the toe or mid-foot) compared to placebo in high-risk patients. Prescribing information suggests the importance of routine preventive foot care, particularly for patients at risk.


Q: Can Vokanamet cause yeast infections in men or women?

A: Yes, regulatory documents list both female genital mycotic infections (very common) and male genital mycotic infections (common) as possible side effects due to the way the drug increases sugar in the urine.


Q: Why is it important to stay hydrated when taking Vokanamet?

A: It is important to stay hydrated because the medication can cause increased urination, which may lead to volume depletion (dehydration) and potentially hypotension (low blood pressure), especially in older patients.


Q: Can Vokanamet cause low blood sugar (hypoglycemia)?

A: Hypoglycemia is generally not a common adverse reaction when Vokanamet is used as monotherapy. However, when it is combined with an insulin secretagogue (like a sulfonylurea) or insulin, low blood sugar is listed as a very common side effect.


Q: Does Vokanamet interact with thyroid medication?

A: In general, the effectiveness of blood sugar medicines may be diminished by certain drugs, including thyroid hormones. Changes in blood sugar control may need to be monitored when thyroid medications are started or stopped.


Q: Can Vokanamet be crushed or split?

A: Official instructions for administration state that the medicine, which is a film-coated tablet, must be swallowed whole with water. The tablet should not be split or crushed.


Q: When must Vokanamet be temporarily stopped before medical procedures?

A: The medicine must be temporarily discontinued before any radiological procedures involving iodinated contrast media (a type of dye) or any major elective surgery. Re-evaluation and confirmation of normal kidney function are required before the medicine may be restarted following a procedure.


Q: What is the difference in how Vokanamet and sulfonylureas work?

A: Vokanamet uses two mechanisms: increasing glucose excretion through the kidneys (Canagliflozin) and decreasing glucose production in the liver (Metformin). Sulfonylureas, in contrast, work differently by stimulating the pancreas to release more insulin.

How should Vokanamet be stored and disposed of?

How to Store and Dispose of Vokanamet?

Vokanamet must be stored according to regulatory specifications to ensure stability. The product is required to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container and must be stored strictly out of the sight and reach of children.

Disposal Requirements

Official guidance dictates that unused or expired Vokanamet must not be thrown away via wastewater or general household trash. To safely discard the medicine, individuals must ask a pharmacist how to dispose of the product or follow specific local pharmaceutical waste regulations. This process ensures compliance with environmental safety standards.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vokanamet found in:

A-Z Index: